The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

Abstract Background Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies. Methods To assess the efficacy and safety of CAR T therapy, we analyzed clinical trials from PUBMED and EMBASE. Results Results...

Full description

Bibliographic Details
Main Authors: Hui Zhou, Yuling Luo, Sha Zhu, Xi Wang, Yunuo Zhao, Xuejin Ou, Tao Zhang, Xuelei Ma
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Cancer
Subjects:
Chimeric antigen receptor T (CAR T) therapy
Safety
Efficacy
Relapsed or refractory B-cell malignancies
Online Access:http://link.springer.com/article/10.1186/s12885-018-4817-4

Internet

http://link.springer.com/article/10.1186/s12885-018-4817-4

Similar Items